Mesalazine and idiopathic intracranial hypertension
Authored by Medicines and Healthcare products Regulatory Agency (MHRA)Originally published 4 Dec 2025
Meets Patient’s editorial guidelines
- DownloadDownload
- Share
- Language
- Discussion
- Ask Patient
- Audio Version
- Add to preferred sources on Google
Medical Professionals
Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find one of our health articles more useful.
Idiopathic intracranial hypertension (IIH) has been very rarely reported in patients treated with mesalazine. Following a recent review, warnings for IIH are being added to the product information for all mesalazine products…
Read the full update from MHRA
About MHRA alerts and recalls
The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’s regulator for medicines, vaccines and medical devices. One of its key responsibilities is to monitor the safety and effectiveness of products in use across the NHS and wider healthcare system. When new safety concerns are identified, or when issues arise with the manufacture or distribution of a medicine or device, the MHRA issues alerts and recalls to protect patients and support healthcare professionals.
These alerts can take several forms. Some provide updated guidance on prescribing or monitoring requirements for medicines and vaccines. Others may highlight newly recognised side effects, or remind clinicians of important risk-mitigation steps. In the case of medical devices, alerts may cover field safety notices, product recalls, or urgent device modifications. All of these communications are designed to ensure that products are used safely and that any risks are managed appropriately.
Patient.info republishes MHRA alerts and recalls so that this information is available quickly and accessibly to both healthcare professionals and the public. The summary above is taken directly from the MHRA’s official publication. To read the full advice, including detailed recommendations for prescribers, manufacturers and patients, please follow the “Read more” link to the MHRA website.
If you are a healthcare professional, you should consult the full notice to confirm the latest prescribing information, monitoring requirements and any actions you need to take in your practice. If you are a patient or carer, do not stop treatment or make changes to your medication or device without first seeking professional advice. If you have any concerns about your medicine or device, speak to your GP, pharmacist or specialist nurse.
Contains public sector information licensed under the Open Government Licence v3.0.
Patient picks for Alerts, recalls and safety information

Professional
Raised intracranial pressure
What is raised intracranial pressure. Indian J Crit Care Med. 2019 Jun;23(Suppl 2):S129-S135. doi: 10.5005/jp-journals-10071-23190. 62028 : Raised Intracranial Pressure Syndrome: A Stepwise Approach. Drugs eg, lithium or tetracyclines Idiopathic or benign intracranial hypertension Idiopathic intracranial hypertension can be caused by obesity,.
by Dr Philippa Vincent, MRCGP

Professional
Idiopathic intracranial hypertension
Synonyms: pseudotumour cerebri, benign intracranial hypertension What is idiopathic intracranial hypertension (IIH). Idiopathic intracranial hypertension (IIH) appears to be due to impaired cerebrospinal fluid (CSF) absorption from the subarachnoid space across the arachnoid villi into the dural sinuses. Epidemiology Idiopathic intracranial.
by Dr Hayley Willacy, FRCGP
%20-%20QOF%20indicator/og.png)
Professional
Hypertension (HYP) - QOF indicator
Hypertension indicators for 2026/27 The hypertension area of QOF assesses blood pressure control using age-specific targets, with equivalent home readings accepted. The distinction between clinic and Home Blood Pressure Monitoring (HBPM) targets follows NICE guidance. Formerly HYP008, this revised indicator reflects the recommendation in NICE.
by Patient infomatics team

Professional
Intracranial venous thrombosis
...is intracranial venous thrombosisThrombosis of cerebral veins or venous sinuses is a much less common cause of cerebral infarction than that caused by arterial disease. National clinical guideline for stroke; Royal College of Physicians (2023) 65683 : RCP National clinical guideline for stroke 2023 Knowledge of the anatomy of venous drainage is.
by Dr Philippa Vincent, MRCGP

Professional
Hypertension
Hypertension is a major risk factor for stroke Cerebrovascular events and heart disease and is therefore one of the most important preventable causes of premature morbidity and mortality in developed and developing countries. Health matters: combating high blood pressure, Public Health England, 2017 59423 : PHE Health matters: combating high blood.
by Dr Colin Tidy, MRCGP

Professional
Borderline personality disorder
It is important to note that the International Classification of Diseases 11th edition (ICD-11) - which came into effect in January 2022 - does not identify different types of personality disorder, and instead focuses on personality traits and severity. In the United States, the DSM-MD5 (the Diagnostic and Statistical Manual of Mental Disorders,.
by Dr Philippa Vincent, MRCGP
Exclusive updates for healthcare professionals
Stay informed with the latest clinical updates, professional insights, and evidence-based guidance. The Patient Pro newsletter curates essential content for healthcare professionals—delivered straight to your inbox.
By subscribing you accept our Privacy Policy. You can unsubscribe at any time. We never sell your data.
Article history
Article also available in English, German, Spanish, French, Italian, Portuguese, Hindi, Hebrew, Arabic, and Swedish.
4 Dec 2025 | Originally published
Authored by:
Medicines and Healthcare products Regulatory Agency (MHRA)
More in alerts, recalls and safety information
- New#MedSafetyWeek (2 to 8 November 2026): Don't ignore suspected side effects, report them! Updates to the Yellow Card website and app
- Amiodarone (Cordarone X): reminder of risks of treatment and need for patient monitoring and supervision
- NewClass 2 Medicines Recall: Accord-UK Ltd, Lercanidipine Hydrochloride 10mg Film-Coated Tablets, EL(26)A/45
- Class 2 Medicines Recall: Beckton Dickson UK Ltd, ChloraPrep 1mL applicator, EL(26)A/34
- Class 2 Medicines Recall: Bristol Laboratories Limited, Phenoxymethylpenicillin 250 mg/5ml Sugar free Oral Solution BP, EL(26)A/33
- Class 2 Medicines Recall: Norgine Pharmaceuticals Limited, Pedmarqsi 80 mg/mL solution for infusion, EL(26)A/42
- NewClass 2 Medicines Recall: Xeal Pharma, Clopidogrel Oral Liquids (all strengths), EL(26)A/43
- Class 3 Medicines Recall: Norgine Limited, MOVICOL Plain 13.7g powder for oral solution, EL(26)A/41
- Class 4 Medicines Defect Notification: Neuraxpharm UK Limited, Levetiracetam Neuraxpharm granules for oral solution in sachet, EL(26)A/40
- NewClass 4 Medicines Defect Notification: Sandoz Limited, Co-Amoxiclav powder for oral suspension 250/62.5 mg/mL, EL(26)A/46
- Cobalt-chrome modular neck hip replacements: risk of metal-wear effects and revision surgery (DSI/2026/010)
- Dräger Atlan Anaesthesia workstations: risk of ventilator failure (DSI/2026/005)
- NewDuvyzat®▼ (givinostat): interim advice on risk mitigation measures following reports of deaths in patients while taking givinostat
- NewField Safety Notices from 02 to 06 November2026.
- Field Safety Notices: 1-5 June 2026
- Field Safety Notices: 12 October 2026 to 16 October 2026
- Field Safety Notices: 15 to 19 June 2026
- Kimal Procedure Packs containing recalled components: Namic Angiographic Syringe with the risk of syringe disconnection; Namic Manifolds with the risk of foreign particulates. Important guidance for use in emergency situations (DSI/2026/002)
- MHRA Safety Roundup: September 2026
- National Patient Safety Alert: ResMed Astral 100 and 150 Ventilators: Potential for Patient Harm due to Unexpected Interruption of Ventilation Therapy (NatPSA/2026/004/MHRA)


